Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.
Journal
Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
18
2
2022
medline:
25
6
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Cardiovascular disease is the most common cause of morbidity and mortality worldwide, and the risk is heightened in the presence of obesity. We review semaglutide, a drug recently approved for chronic weight management in adults with obesity or who are overweight. On 4 June 2021, the US Food and Drug Administration approved semaglutide injection at 2.4 mg once weekly for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes mellitus, or high cholesterol. This subcutaneous injection is the first approved drug for chronic weight management in adults with general obesity or overweight since 2014. The drug is indicated for weight management in patients with a BMI of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater. Semaglutide offers adults with obesity or overweight a new treatment in conjunction with a weight management program consisting of reduced calorie diet and increased physical activity.
Identifiants
pubmed: 35175229
doi: 10.1097/HCO.0000000000000955
pii: 00001573-202207000-00008
doi:
Substances chimiques
Hypoglycemic Agents
0
semaglutide
53AXN4NNHX
Glucagon-Like Peptides
62340-29-8
Banques de données
ClinicalTrials.gov
['NCT03574597']
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
350-355Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Said S, Mukherjee D, Whayne TF. Interrelationships with metabolic syndrome, obesity and cardiovascular risk. Curr Vasc Pharmacol 2016; 14:415–425.
Patham B, Mukherjee D, San Juan ZT. Contemporary review of drugs used to treat obesity. Cardiovasc Hematol Agents Med Chem 2013; 11:272–280.
Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med 2019; 381:2440–2450.
Ward ZJ, Long MW, Resch SC, et al. Simulation of growth trajectories of childhood obesity into adulthood. N Engl J Med 2017; 377:2145–2153.
Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation 2021; 143:e254–e743.
Goldenberg RM, Steen O. Semaglutide: review and place in therapy for adults with type 2 diabetes. Can J Diabetes 2019; 43:136–145.
Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365:1597–1604.
Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract 2016; 22: (Suppl 3): 1–203.
Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ 2020; 192:E875–E891.
Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts 2015; 8:402–424.
Bessesen DH, Van Gaal LF. Progress and challenges in antiobesity pharmacotherapy. Lancet Diabetes Endocrinol 2018; 6:237–248.
Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352:167–172.
Lei X-G, Ruan J-Q, Lai C, et al. Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity 2021; 29:985–994.
Salari N, Jafari S, Darvishi N, et al. The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Diabetol Metab Syndr 2021; 13:110.
Carbone EA, Caroleo M, Rania M, et al. An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. Eat Weight Disord 2021; 26:779–788.
Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 2021; 384:1719–1730.
Ryan DH. Next generation antiobesity medications: setmelanotide, semaglu-tide, tirzepatide and bimagrumab: what do they mean for clinical practice? J Obes Metab Syndr 2021; 30:196–208.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384:989.
Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021; 397:971–984.
Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021; 325:1403–1413.
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021; 325:1414–1425.
Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022; 327:138–150.
Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384:1113–1124.
He K, Guo Q, Zhang H, et al. Once-weekly semaglutide for obesity or overweight: a systematic review and meta-analysis. Diabetes Obes Metab 2021; doi: 10.1111/dom.14612.
doi: 10.1111/dom.14612
Zhong P, Zeng H, Huang M, et al. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine 2022; doi: 10.1007/s12020-021-02945-1.
doi: 10.1007/s12020-021-02945-1
Lee M, Lauren BN, Zhan T, et al. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract 2020; 6:162–170.